Literature DB >> 25540309

Comorbidity increases the risk of hospitalizations in multiple sclerosis.

Ruth Ann Marrie1, Lawrence Elliott2, James Marriott2, Michael Cossoy2, Aruni Tennakoon2, Nancy Yu2.   

Abstract

OBJECTIVE: We aimed to evaluate the association between comorbidity and rates of hospitalization in the multiple sclerosis (MS) population as compared to a matched cohort from the general population.
METHODS: Using population-based administrative data from the Canadian province of Manitoba, we identified 4,875 persons with MS and a matched general population cohort of 24,533 persons. We identified all acute care hospitalizations in the period 2007-2011. Using general linear models, we evaluated the association between comorbidity status and hospitalization rates (all-cause, non-MS-related, MS-related) in the 2 populations, adjusting for age, sex, and socioeconomic status.
RESULTS: Comorbidity was common in both cohorts. Over the 5-year study period, the MS population had a 1.5-fold higher hospitalization rate (adjusted rate ratio [aRR] 1.56; 95% confidence interval [CI] 1.44-1.68) than the matched population. Any comorbidity was associated with a 2-fold increased risk of non-MS-related hospitalization rates (aRR 2.21; 95% CI 1.73-2.82) in the MS population, but a nearly 4-fold increase in hospitalization rates in the matched population (aRR 3.85; 95% CI 3.40-4.35). Comorbidity was not associated with rates of hospitalization for MS-related reasons, regardless of how comorbidity status was defined.
CONCLUSIONS: In the MS population, comorbidity is associated with an increased risk of all-cause hospitalizations, suggesting that the prevention and management of comorbidity may reduce hospitalizations.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Year:  2014        PMID: 25540309      PMCID: PMC4336005          DOI: 10.1212/WNL.0000000000001187

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  33 in total

1.  Health care resource utilization in inflammatory bowel disease.

Authors:  Teresa Longobardi; Charles N Bernstein
Journal:  Clin Gastroenterol Hepatol       Date:  2006-05-02       Impact factor: 11.382

2.  National health surveys and the behavioral model of health services use.

Authors:  Ronald Max Andersen
Journal:  Med Care       Date:  2008-07       Impact factor: 2.983

3.  Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study.

Authors:  Ruth Ann Marrie; Bo N Yu; Stella Leung; Lawrence Elliott; Patricia Caetano; Sharon Warren; Christina Wolfson; Scott B Patten; Lawrence W Svenson; Helen Tremlett; John Fisk; James F Blanchard
Journal:  Mult Scler Relat Disord       Date:  2013-04-02       Impact factor: 4.339

4.  The treatment of unrelated disorders in patients with chronic medical diseases.

Authors:  D A Redelmeier; S H Tan; G L Booth
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

5.  Socioeconomic trends in hospitalization for multiple sclerosis.

Authors:  Shivanand P Lad; Christopher H Chapman; Michael Vaninetti; Lawrence Steinman; Ari Green; Maxwell Boakye
Journal:  Neuroepidemiology       Date:  2010-06-15       Impact factor: 3.282

6.  The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study.

Authors:  Ruth Ann Marrie; Bo Nancy Yu; Stella Leung; Lawrence Elliott; Patricia Caetano; Sharon Warren; Christina Wolfson; Scott B Patten; Lawrence W Svenson; Helen Tremlett; John Fisk; James F Blanchard
Journal:  Neuroepidemiology       Date:  2012-10-24       Impact factor: 3.282

7.  Adverse lipid profile is not associated with relapse risk in MS: results from an observational cohort study.

Authors:  Prudence Tettey; Steve Simpson; Bruce Taylor; Leigh Blizzard; Anne-Louise Ponsonby; Terence Dwyer; Karam Kostner; Ingrid van der Mei
Journal:  J Neurol Sci       Date:  2014-03-05       Impact factor: 3.181

8.  Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.

Authors:  Bianca Weinstock-Guttman; Robert Zivadinov; Dana Horakova; Eva Havrdova; Jun Qu; Grace Shyh; Elizabeth Lakota; Kerri O'Connor; Darlene Badgett; Miriam Tamaño-Blanco; Michaela Tyblova; Sara Hussein; Niels Bergsland; Laura Willis; Jan Krasensky; Manuela Vaneckova; Zdenek Seidl; Murali Ramanathan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-04-17       Impact factor: 10.154

9.  Dramatically changing rates and reasons for hospitalization in multiple sclerosis.

Authors:  Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; James Blanchard; Aruni Tennakoon; Nancy Yu
Journal:  Neurology       Date:  2014-08-01       Impact factor: 9.910

10.  Health status and health care utilization of multiple sclerosis in Canada.

Authors:  Sheri L Pohar; C Allyson Jones; Sharon Warren; Karen V L Turpin; Kenneth Warren
Journal:  Can J Neurol Sci       Date:  2007-05       Impact factor: 2.104

View more
  27 in total

1.  Comorbidity in Multiple Sclerosis: Some Answers, More Questions.

Authors:  Ruth Ann Marrie
Journal:  Int J MS Care       Date:  2016 Nov-Dec

Review 2.  Wellness and the Role of Comorbidities in Multiple Sclerosis.

Authors:  Brandon P Moss; Mary R Rensel; Carrie M Hersh
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

3.  Effects of physical comorbidities on disability progression in multiple sclerosis.

Authors:  Tingting Zhang; Helen Tremlett; Feng Zhu; Elaine Kingwell; John D Fisk; Virender Bhan; Trudy Campbell; Karen Stadnyk; Robert Carruthers; Christina Wolfson; Sharon Warren; Ruth Ann Marrie
Journal:  Neurology       Date:  2018-01-03       Impact factor: 9.910

4.  Hospital admission rates for pediatric multiple sclerosis in the United States using the Pediatric Health Information System (PHIS).

Authors:  Amy M Lavery; Brenda L Banwell; Geraldine Liu; Amy T Waldman
Journal:  Mult Scler Relat Disord       Date:  2016-06-08       Impact factor: 4.339

Review 5.  Comorbidity in multiple sclerosis: implications for patient care.

Authors:  Ruth Ann Marrie
Journal:  Nat Rev Neurol       Date:  2017-03-17       Impact factor: 42.937

Review 6.  The Evidence for Dietary Interventions and Nutritional Supplements as Treatment Options in Multiple Sclerosis: a Review.

Authors:  Leah J Mische; Ellen M Mowry
Journal:  Curr Treat Options Neurol       Date:  2018-03-17       Impact factor: 3.598

7.  Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.

Authors:  Kaarina Kowalec; Kyla A McKay; Scott B Patten; John D Fisk; Charity Evans; Helen Tremlett; Ruth Ann Marrie
Journal:  Neurology       Date:  2017-11-08       Impact factor: 9.910

8.  The prevalence of comorbidities in patients with multiple sclerosis: population-based registry data.

Authors:  Gorica D Maric; Tatjana D Pekmezovic; Sarlota T Mesaros; Olivera S Tamas; Jovana B Ivanovic; Vanja N Martinovic; Marko M Andabaka; Aleksa Lj Jovanovic; Nikola D Veselinovic; Darija B Kisic-Tepavcevic; Jelena S Drulovic
Journal:  Neurol Sci       Date:  2020-09-22       Impact factor: 3.307

9.  Ten-year trajectories of health care utilization by Manitobans with MS predict nursing home entry.

Authors:  Marcia Finlayson; Okechukwu Ekuma; Greg Finlayson; Depeng Jiang; Ruth Ann Marrie
Journal:  Neurol Clin Pract       Date:  2019-02

10.  Flammer syndrome in multiple sclerosis: diagnostics, prediction, and personalization of treatments.

Authors:  Cihat Uzunköprü; Yeşim Beckmann
Journal:  EPMA J       Date:  2019-08-10       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.